Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$983.00K$983.00K−12.1% vs Q3 2018 Net Income-$55.32M-$55.32MN/M vs Q3 2018 EPS Diluted-$1.34-$1.34N/M vs Q3 2018 Operating Income-$22,864,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$24,181,000N/M Margins · derivedOperating margin-2325.9%−417.0 pt vs Q3 2018
Net margin-5627.6%−2699.1 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end